MOLECULAR NET DIAGNOSTIC
A liquid biopsy neuroendocrine tumor diagnostic to help oncologists better manage NETs
The NETest is a blood-based neuroendocrine cancer diagnostic that can be used to help diagnose, recommend treatment, and then monitor progress for neuroendocrine tumor (NET) or neuroendocrine neoplasia (NEN) patients in real-time.
Quick and non-invasive, results from this novel liquid biopsy can be shared within 48 hours of receiving a blood sample. Upon receipt at our CAP and CLIA-certified lab, we use a quantitative polymerase chain reaction (qPCR) method to measure the expression levels of 51 genes related to neuroendocrine cancer. We then employ our multianalyte algorithmic analyses (MAAA) to calculate the likelihood of a patient having a NET or NEN. We then share that likelihood or risk score with your oncologist. Learn more about Our Science.
The NETest, which has been used over 10,000 times in medical centers throughout the United States, delivers higher levels of sensitivity, specificity, and accuracy than any other testing method available today. It helps oncologists and patients manage and monitor treatment and quickly detect the recurrence of disease.
NETest by the Numbers
Prior to and since its introduction in 2014, the NETest has been the subject of 63 peer-review articles, clinical studies, and scientific journal entries. After a decade of study, and over 10,000 use cases in the US alone, the empirical evidence is clear: NETest outperforms all molecular and non-molecular biomarkers in neuroendocrine tumor diagnosis and management.
10,000+ NETests Utilized
Prominent Oncologists Worldwide have recommended the NETest
Since the first commercial sale of the NETest shortly after our founding in 2014, over 10,000 NETests have been used by doctors and oncologists affiliated with some of the most well-respected Cancer Centers across the United States. Visit our NETest Resources Page to learn more
View a Sample Test
Interested in seeing a sample lab report for the NETest, detailing test methodology, score calculation, and sample NETest results? Then click below to download a .pdf.
Featured NETest Resources
The latest Peer-Reviewed Papers and News Coverage of the NETest
Analysis of ten studies indicates the NETest is an accurate (>95%) biomarker suitable for clinical use in NET disease management, exhibiting utility as an IVD to establish a diagnosis and monitor therapeutic efficacy.
The NETest PPQ–Peptide Receptor Radionuclide Therapy Predictor Quotient–exhibits over 97% accuracy in predicting positive response to PRRT for metastatic/inoperable NETs in real time.
Neuroendocrine Neoplasia Diagnosis: mRNA biomarker NETest exhibits 3-5 times greater accuracy than Chromogranin A
NETest, a multigenomic mRNA biomarker exhibiting ~99% accuracy in NEN disease identification; is far more accurate than CgA (19–33%) and should be considered the biomarker standard of care.
An interview with the Co-Inventor of the NETest
“The NETest fulfills a completely unmet need in neuroendocrine tumor disease: there have been no biomarkers that are effective or accurate. This is a multi-genomic test and it is about 95% accurate and 95% sensitive. It makes the diagnosis of neuroendocrine tumors, then allows you to monitor neuroendocrine tumors to see if the disease is stable or progressive.”
Dr. Irvin M. Modlin
Founder of Wren Laboratories and co-developer of the NETest
HOW IT WORKS
The NETest Testing Process
LOCAL LABORATORY & DOCTORS OFFICE
A Non-Invasive Blood Draw
Obtain a requisition from your physician and get your blood sample drawn at your local laboratory.
The blood sample with the requisition form is sent via overnight courier to the clinical testing laboratory at Wren Laboratories, Branford, CT.
Testing is Performed
The laboratory performs all testing necessary to generate a NETest result – typically takes two full days.
Results are Generated
Once the NETest result is produced and verified, it is sent to your doctor.
CLINICAL INSTITUTION / DOCTORS OFFICE
Your doctor interprets the NETest result in conjunction with other clinical assessments.
Your doctor notifies you of the results.